Assuming research into individual Rapamycin and Metformin effectiveness shows promise, by December 31, 2041, will a peer reviewed, randomised controlled trial comparing combination therapy (Rapamycin and Metformin) to monotherapy (either Rapamycin or Metformin alone) and placebo in healthy individuals aged 50 and above shows a statistically significant increment in median lifespan or there is a measurable decrement of biological ageing than it earlier was, compared to monotherapy, with results meeting p-value of less than 5% (0.05).

Open on Seer · accepts answers from Mon 31 Dec, 00:00 UTC · OddsFlow orders stop filling the moment the question gets its first answer. Place an order on this market